Dermal Cell News Volume 7.09 | Mar 15 2021

    0
    135






    2021-03-15 | DCN 7.08


    Dermal Cell News by STEMCELL Technologies
    Vol. 7.09 – 15 March, 2021
    TOP STORY

    A Pulsatile Release Platform Based on Photo-Induced Imine-Crosslinking Hydrogel Promotes Scarless Wound Healing

    Scientists developed a wound dressing material based on an integrated photo-crosslinking strategy and a microcapsule platform with pulsatile release of TGF-β inhibitor to achieve spatiotemporal specificity for skin wounds.
    [Nature Communications]

    Full Article

    Connect with us via LiveChat to ask your scientific support questions
    PUBLICATIONSRanked by the impact factor of the journal

    Inhibiting the MNK1/2-eiF4E Axis Impairs Melanoma Phenotype Switching and Potentiates Anti-Tumor Immune Responses

    The authors demonstrated that blocking the MNK1/2-eIF4E axis inhibited melanoma phenotype switching and sensitized melanoma to anti-PD-1 immunotherapy. They showed that phospho-eIF4E-deficient murine melanomas expressed high levels of melanocytic antigens, with similar results verified in patient melanomas.
    [Journal of Clinical Investigation]

    AbstractFull ArticleGraphical Abstract

    RAF-Mutant Melanomas Differentially Depend on ERK2 over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

    Investigators demonstrated that ERK2 drove BRAF-mutant melanoma gene expression and proliferation as a function of its higher expression compared to ERK1.
    [Molecular Cancer Research]

    Abstract

    FAM129B‐Dependent Activation of NRF2 Promotes an Invasive Phenotype in BRAF Mutant Melanoma Cells

    Researchers demonstrated that activation of NRF2 by FAM129B contributed to increased metastatic potential of BRAF V600E mutant melanoma cells.
    [Molecular Carcinogenesis]

    Abstract

    Twist1 is Required for the Development of UVB‐Induced Squamous Cell Carcinoma

    Scientists showed that Twist1 had a direct role in maintaining the balance between proliferation and differentiation of keratinocytes and keratinocyte stem/progenitor populations.
    [Molecular Carcinogenesis]

    Abstract

    mTOR Inhibitor INK128 Promotes Wound Healing by Regulating MDSCs

    Mice models of normal, diabetic, and diabetic+INK128 were constructed. Bone marrow-derived macrophages and RAW264.7 cell line co-cultured with myeloid-derived suppressor cells (MDSCs), which were induced at different conditions. Flow cytometry, western blot, quantitative real-time PCR, and immunohistochemical analysis were performed.
    [Stem Cell Research & Therapy]

    Full Article

    A Novel Role for Bone Marrow-Derived Cells to Recover Damaged Keratinocytes from Radiation-Induced Injury

    Researchers investigated the role of bone marrow-derived cells (BMDCs) in radiation-induced skin injury in bone marrow transplantation mice and observed that BMDCs contributed to skin recovery after ionizing radiation-induced barrier dysfunction.
    [Scientific Reports]

    Full Article

    Request a free copy of the Growing Organoids from Stem Cells Wallchart
    REVIEWS

    Epigenetic Regulation of Cellular Functions in Wound Healing

    The authors discuss the epigenetic changes that occur during wound healing and the rapidly expanding understanding of how these mechanisms affect healing resolution in both acute and chronic wound milieu. They also provide a focused overview of current research into epigenetic regulators that contribute to wound healing by specific cell type.
    [Experimental Dermatology]

    Full Article

    INDUSTRY AND POLICY NEWS

    BiomX Announces Dosing of First Subject in Phase II Study of BX001 for Acne-Prone Skin

    BiomX, Inc. announced that the first subject has been dosed in a Phase II cosmetic clinical study of BX001 in subjects with mild-to-moderate acne.
    [BiomX, Inc.]

    Press Release

    Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase III Alopecia Areata (AA) Trial

    Eli Lilly and Company and Incyte, Inc. announced top-line results from BRAVE-AA2, a Phase III study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata.
    [Incyte, Inc.]

    Press Release

    FEATURED EVENT

    ISSCR 2021 Annual Meeting

    June 21 – 26, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Associate Researcher – Developmental and Regenerative Biology

    Mount Sinai Health System – New York, New York, United States

    Postdoctoral Fellow – Diet and Melanoma

    MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Fellow – Experimental Dermatology

    University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Scholar – Immune Responses in Human Skin and Mucosal Surfaces

    University of Washington – Seattle, Washington, United States

    Research Assistant – Melanoma Research

    Portland VA Research Foundation – Portland, Oregon, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Dermal Cell News Twitter